Positive top-line results for Pfizer's Prevenar 13 in pneumonia in over 65s

US pharma behemoth Pfizer (NYSE: PFE) says that top-line results from a study of Prevenar 13 (pneumococcal 13-valent conjugate vaccine) show it met its primary and secondary goals in a study of older patients.

The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the landmark study of around 85,000 subjects evaluating the efficacy of Prevenar 13in adults 65 years of age and older, achieved its primary clinical objective and both secondary clinical objectives. CAPiTA is the largest double-blind, randomized, placebo-controlled vaccine efficacy trial ever conducted in adults.

The primary objective of the study was to demonstrate efficacy of Prevenar 13 against a first episode of vaccine-type community-acquired pneumonia (CAP). The CAPiTA study also met both secondary objectives, which were efficacy against (i) a first episode of non-bacteremic/non-invasive vaccine-type CAP and (ii) a first episode of vaccine-type invasive pneumococcal disease (IPD).